×
About 2,253 results

ALLMedicine™ Chorea Center

Research & Reviews  739 results

The challenges in diagnosing pediatric primary antiphospholipid syndrome.
https://doi.org/10.1177/09612033221108853
Lupus Demir S, Keskin A et. al.

Jun 25th, 2022 - Pediatric primary antiphospholipid syndrome (APS) is a very rare disease with significant distinctions from the APS in adults. Herein, we present our experience in the diagnosis and treatment of six pediatric primary APS patients, who met the upda...

NIAID Clinical Center Genomics Opportunity Protocol
https://clinicaltrials.gov/ct2/show/NCT02417766

Jun 24th, 2022 - Investigators at National Institute of Allergy and Infectious Diseases (NIAID) are actively developing the infrastructure and capability for identifying the cause of heterogeneous immune-mediated disorders through whole exome and whole genome sequ...

A Study of TEV-50717 (Deutetrabenazine) for the Treatment of Dyskinesia in Cerebral Palsy in Children and Adolescents
https://clinicaltrials.gov/ct2/show/NCT03813238

Jun 22nd, 2022 - CP (cerebral palsy) refers to a group of neurological disorders that appear in infancy or early childhood and permanently affect body movement and muscle coordination. CP is caused by damage to or abnormalities inside the developing brain that dis...

Breastfeeding does not protect against the development of carditis in children with acu...
https://doi.org/10.1017/S1047951122001834
Cardiology in the Young; Gurbuz F, Canbulat Sahiner N et. al.

Jun 21st, 2022 - Acute rheumatic fever is an autoimmune disease that develops due to streptococcal infection. The positive effect of breastfeeding on the development of the child's immune system is well documented. In this study, we aimed to investigate the effect...

Highlighting the Dystonic Phenotype Related to GNAO1.
https://doi.org/10.1002/mds.29074
Movement Disorders : Official Journal of the Movement Dis... Wirth T, Garone G et. al.

Jun 21st, 2022 - Most reported patients carrying GNAO1 mutations showed a severe phenotype characterized by early-onset epileptic encephalopathy and/or chorea. The aim was to characterize the clinical and genetic features of patients with mild GNAO1-related phenot...

see more →

Guidelines  1 results

EULAR recommendations for the management of systemic lupus erythematosus with neuropsyc...
https://doi.org/10.1136/ard.2010.130476
Annals of the Rheumatic Diseases; Bertsias GK, Ioannidis JP et. al.

Aug 21st, 2010 - To develop recommendations for the diagnosis, prevention and treatment of neuropsychiatric systemic lupus erythematosus (NPSLE) manifestations. The authors compiled questions on prevalence and risk factors, diagnosis and monitoring, therapy and pr...

see more →

Drugs  65 results see all →

Clinicaltrials.gov  42 results

NIAID Clinical Center Genomics Opportunity Protocol
https://clinicaltrials.gov/ct2/show/NCT02417766

Jun 24th, 2022 - Investigators at National Institute of Allergy and Infectious Diseases (NIAID) are actively developing the infrastructure and capability for identifying the cause of heterogeneous immune-mediated disorders through whole exome and whole genome sequ...

A Study of TEV-50717 (Deutetrabenazine) for the Treatment of Dyskinesia in Cerebral Palsy in Children and Adolescents
https://clinicaltrials.gov/ct2/show/NCT03813238

Jun 22nd, 2022 - CP (cerebral palsy) refers to a group of neurological disorders that appear in infancy or early childhood and permanently affect body movement and muscle coordination. CP is caused by damage to or abnormalities inside the developing brain that dis...

Abnormal Hyperkinetic Movements Post Acute Stroke
https://clinicaltrials.gov/ct2/show/NCT05388552

May 25th, 2022 - The occurrence of abnormal movements is a frequent reason for consultation in neurology. The etiologies are broadly separated into "primary causes", in example intrinsically neurological diseases (of genetic or degenerative origin), and "secondary...

Open-Label Rollover Study for Continuing Valbenazine Administration for the Treatment of Chorea Associated With Huntington Disease
https://clinicaltrials.gov/ct2/show/NCT04400331

Apr 11th, 2022 - This is a Phase 3, open-label study to evaluate the long-term safety and tolerability of valbenazine, and to provide subjects continued access to valbenazine for the treatment of chorea associated with Huntington disease.

Energy Balance in Huntington's Disease. A Multidisciplinary Study Approach for a Complex Problem (BEHD-EM)
https://clinicaltrials.gov/ct2/show/NCT05250323

Feb 22nd, 2022 - In the last decade, numerous studies have been published showing how epigenetic (environmental) factors can modify the clinical manifestations of diseases of genetic origin. Specifically, epidemiological studies have observed that physical exercis...

see more →

News  49 results

Tardive Dyskinesia Drug Safe, Effective for Huntington's Chorea
https://www.medscape.com/viewarticle/972355

Apr 19th, 2022 - A drug currently approved for tardive dyskinesia (TD) is also effective at treating Huntington's disease (HD)–associated chorea, a movement disorder that affects most patients with HD, new phase 3 trial results show. Valbenazine is in the same cla...

Top strategies for preventing tardive dyskinesia
https://www.mdedge.com/psychiatry/article/251979/movement-disorders/top-strategies-preventing-tardive-dyskinesia
Doug Brunk

Feb 18th, 2022 - LAS VEGAS – In the opinion of Christoph U. Correll, MD, tardive dyskinesia (TD) “has been somewhat forgotten” by psychiatrists because the risk of patients developing the condition is considered to be significantly lower with second-generation ant.

Fast Five Quiz: Huntington Disease Signs and Symptoms
https://reference.medscape.com/viewarticle/929783_6

May 27th, 2020 - Initiation of saccadic movements is slow and uncoordinated, and smooth pursuit is interrupted by saccadic intrusions. Patients are unable to inhibit saccades toward a peripheral stimulus when instructed to look in the opposite direction. Eye movem...

Fast Five Quiz: Huntington Disease
https://reference.medscape.com/viewarticle/929780

May 27th, 2020 - Huntington disease (HD) is a genetic neurodegenerative disorder named after Dr George Huntington, who in 1872 reported his observations of dementia and chorea that ran in families on the East End of Long Island, New York. The disease is now known ...

Fast Five Quiz: Huntington Disease
https://reference.medscape.com/viewarticle/929780_3

May 27th, 2020 - The initial stages of Huntington disease are often characterized by deficits in short-term memory. This is frequently followed by motor dysfunction and a variety of cognitive changes, including diminished verbal fluency and problems with attention...

see more →

Patient Education  5 results see all →